Eli Lilly and Company (NYSE:LLY) saw an upside of 1.02% to close Monday at $454.08 after adding $4.59 on the day. The 5-day average trading volume is 2,167,460 shares of the company’s common stock. It has gained $461.64 in the past week and touched a new high 2 times within the past 5 days. An average of 2,315,475 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,524,342.
LLY’s 1-month performance is 0.44% or $2.00 on its low of $434.34 reached on 07/13/23. The company’s shares have touched a 52-week low of $296.32 and high of $469.87, with the stock’s rally to the 52-week high happening on 06/30/23. YTD, LLY has achieved 24.12% or $88.24 and has reached a new high 26 times. However, the current price is down -3.36% from the 52-week high price.
Insider Transactions
LLY stock investors last saw insider trading activity on Jul 21.LILLY ENDOWMENT INC (10% Owner) most recently sold 591 shares at $466.62 per share on Jul 21. This transaction cost the insider $275,773. 10% Owner, LILLY ENDOWMENT INC, sold 164,125 shares at a price of $467.60 on Jun 30. Then, on Jun 29, 10% Owner LILLY ENDOWMENT INC sold 44,115 shares at a price of $465.08 per share. This transaction amounted to $20,517,137.
Valuation Metrics
LLY stock has a beta of 0.35. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 15.55 while the price-to-book (PB) in the most recent quarter is 36.56, with the price to cash flow ratio at 3650.26.
Eli Lilly and Company’s quick ratio for the recent period was 1.00, with the current ratio over the same period at 1.30. In terms of profitability, the gross margin trailing 12 months is 77.70%. The trailing 12-month EBITDA margin is 34.35%. The firm’s gross profit as reported stood at $21.91 billion against revenue of $28.54 billion.
Earnings Surprise
Eli Lilly and Company’s cash and short-term investments amounted to $123.4 million against total debt of $18.99 billion. Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -41.49% to $1.34 billion, while revenue of $1.94 billion was -44.08% off the previous quarter. EBITDA for the quarter stood at more than $1.86 billion. LLY stock balance sheet for the recent quarter shows that total liabilities totaled 41.87 billion, with total debt at $18.99 billion. Shareholders hold equity totaling $949.27 million.
Let’s look briefly at Eli Lilly and Company (LLY) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 07 August was 51.01% to suggest the stock is trending Neutral, with historical volatility in this time period at 11.49%.
The stock’s 5-day moving average is $452.06, reflecting a -0.10% or -$0.47 change from its current price. LLY is currently trading +0.20% above its 20-day SMA, +38.83% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +6.65% and SMA200 by+35.53%.
Stochastic %K and %D was 27.25% and 34.77% and the average true range (ATR) pointed at 7.57. The RSI (14) points at 51.62%, while the 14-day stochastic is at 36.72% with the period’s ATR at 8.02. The stock’s 9-day MACD Oscillator is pointing at -2.64 and -4.67 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Eli Lilly and Company (NYSE: LLY), Citigroup reiterated its a Buy rating for the company but lifted their price target by $360 to $525. Analysts offering their rating for LLY stock have a consensus rating for the stock as Overweight. Currently, 1 brokerage advisors rate LLY as a “sell,”, while 7 advise that investors “Hold.” 1 analysts have rated the stock as underweight. 2 rates the stock as overweight while 19 have offered a “buy” rating.
What is LLY’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $300.00 and a high of $565.00, with their median price target at $500.00. Looking at these predictions, the average price target given by analysts is for Eli Lilly and Company (LLY) stock is $479.49.
